The link you have chosen leads to a site maintained by a third party over whom Bracco has no control.
As such, Bracco makes no representation as to the accuracy or any other aspect of the information on this site.
Do you want to continue?
OK
Cancel
Philochem and Bracco Imaging collaborate on the development of a molecule for diagnostic applications
Siena-Milan, Italy ,
03/22/2022
Philochem, a subsidiary of the Philogen Group, and Bracco Imaging today announce that they have entered into a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications, with proven ability to selectively detect a variety of metastatic solid tumors in cancer patients, paving the way for a new approach to tumor diagnosis.